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Drug and alcohol dependence often go hand in hand. Research 
shows that people who are dependent on alcohol are much 
more likely than the general population to use drugs, and people 
with drug dependence are much more likely to drink alcohol 
(1). For example, Staines and colleagues (2) found that, of 248 
alcoholics seeking treatment, 64 percent met the criteria for 
a drug use disorder at some point in their lifetime. 
Patients with co-occurring alcohol and other drug use disorders 
also are likely to have more severe dependence-related prob­
lems than those without combined disorders—that is, they 
meet a higher number of diagnostic criteria for each disorder 
(three out of seven criteria are required to meet the diagnosis 
of dependence) (3). People with co-occurring alcohol and 
other drug use disorders are more likely to have psychiatric 
disorders such as personality, mood, and anxiety disorders; 
they are more likely to attempt suicide and to suffer health 
problems (3). People who use both alcohol and drugs also are 
at risk for dangerous interactions between these substances. 
For example, a person who uses alcohol with benzodiazepines, 
whether these drugs are prescribed or taken illegally, is at 
increased risk of fatal poisoning (3). 
This Alcohol Alert features the latest research on alcohol and 
other drug use disorders, examining the frequency with which 
these disorders occur and overlap, evidence for common 
genetic risk factors, and how co-occurring disorders can be 
most effectively diagnosed and treated. 
Epidemiology: How Common 
Is Alcohol and Other Drug 
Addiction? 
How common is alcohol and other drug use, and how often 
do alcohol and drug use disorders co-occur? To answer these 
questions, the National Institute on Alcohol Abuse and 
Alcoholism (NIAAA) conducted the National Epidemiologic 
Survey on Alcohol and Related Conditions (NESARC), one 
of the largest surveys of its kind ever performed. It examined 
the prevalence of alcohol and other drug use and abuse in 
the United States. According to NESARC, 8.5 percent of 
adults in the United States met the criteria for an alcohol use 
disorder, whereas 2 percent met the criteria for a drug use 
disorder and 1.1 percent met the criteria for both. People 
who are dependent on drugs are more likely to have an alco­
hol use disorder than people with alcoholism are to have a 
drug use disorder. Young people ages 18–24 had the highest 
rates of co-occurring alcohol and 
other drug use disorders (see figure). 
Men were more likely than women to 
have problems with alcohol, drugs, 
or the two substances combined (1). 
Because many people suffer from 
both alcohol and drug dependence, 
scientists speculate that these disorders 
“ Because many people suffer from both 
alcohol and drug dependence, scientists 
speculate that these disorders may have 
some common causes and risk factors.” 
Prevalence of alcohol and drug use disorders by age in the United States 
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may have some common causes and risk factors, as 
described below. 
The Genetics of Alcohol and 
Other Drug Use Disorders— 
Shared Risk Factors? 
Research has established that some of the risk for addiction 
to both drugs and alcohol is inherited. Children of alco­
holics are 50 to 60 percent more likely to develop alcohol 
use disorders than people in the general population (4). 
Similarly, children of parents who abuse illicit drugs may be 
45 to 79 percent more likely to do so themselves than the 
general public (5–7). This suggests that some of the risk 
factors for alcohol and other drug use are rooted in genetics, 
though studies of specific families have not proven a genetic 
contribution. 
Researchers believe that some of the same genes that increase 
a person’s risk for problems with alcohol also might put him 
or her at greater risk for drug dependence. Moreover, those 
same genes might increase the risk for other psychiatric 
problems, such as conduct disorder and adult antisocial 
behavior (i.e., externalizing behaviors) (8). 
Much of the most compelling evidence for this apparent 
genetic link is based on twin and adoption studies.1 For 
example, in 2003, Kendler and colleagues (9) analyzed data 
from the Virginia Twin Registry. They compared rates of 
alcohol, drug, and other externalizing disorders in identical 
and fraternal twins. They found that, in identical twins, 
when one twin was dependent on alcohol or on drugs, the 
second twin was much more likely (than a second fraternal 
twin) to have a problem with drugs or alcohol or to have 
an externalizing disorder. The study suggested that certain 
genes put people at risk for both alcohol and other drug use 
disorders, as well as externalizing disorders, whereas other 
genes put people at risk for specific types of disorders. These 
disorder-specific genes often are linked to how the body 
breaks down (or metabolizes) specific drugs and alcohol (8). 
Diagnosing Substance Use 
Disorders: Barriers and 
Challenges 
An accurate diagnosis is the first step toward treatment and 
recovery. However, diagnosing people with drug and alco­
hol disorders can be complicated, especially when these dis­
orders occur concurrently. There are barriers to diagnosis: 
For example, patients may be unwilling to talk about their 
addiction, and clinicians may be unaware of the signs and 
symptoms of abuse and dependence. 
Clinicians should screen patients for alcohol and other drug 
use disorders in a systematic, step-by-step fashion. One 
resource that can help is NIAAA’s publication Helping 
Patients Who Drink Too Much: A Clinician’s Guide. The Guide 
takes clinicians through a series of steps, outlining what 
questions to ask patients. It presents information—such as 
defining a standard drink and the recommended daily and 
weekly drinking limits—that can help both clinicians and 
1 Adoption studies compare the risk of alcoholism in biological relatives with the risk in 
adoptive relatives of alcoholics (e.g., an adopted-away child of an alcoholic parent). Twin 
studies compare the risk of alcoholism in pairs of twins reared in the same environment, 
examining both identical twins (i.e., twins who share 100 percent of their genes) and frater­
nal twins (i.e., twins who share, on average, only 50 percent of their genes). 
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patients identify problem-drinking behaviors. (For more infor­
mation on the Guide, see the resources section of this Alert.) 
Clinicians also may screen patients for drug problems using 
instruments such as the Drug Abuse Screening Test (DAST) 
or the CAGE Adapted to Include Drugs (CAGE–AID), 
or using a urine drug test (3). Clinicians should take a full 
history of any patient suspected of having a problem with 
drugs, asking, for example, about which drugs are used, age 
of first use, pattern of use, consequences of use, attempts 
to quit, and treatment history. It also is crucial to evaluate 
patients for signs of intoxication or withdrawal. Clinicians 
should assess the patient’s psychiatric history, medical his­
tory, family history, and social and developmental history. 
With this information, clinicians will be better equipped to 
determine whether the patient fits the DSM–IV–TR2 crite­
ria for substance abuse or dependence (3). 
Despite careful screening, however, some substance use dis­
orders go undetected. Patients often misreport their sub­
stance use because of the stigma associated with an alcohol 
or other drug use disorder diagnosis, or they may fear legal 
reprisals. To address these fears, clinicians should make sure 
patients know the scope of confidentiality required by law. 
Clinicians also should make an effort to be empathic, 
accepting, and nonjudgmental; to ask questions in a direct 
and straightforward manner; and to deal with their own 
discomfort regarding drug use so as not to communicate 
their anxiety to their patients (3). 
Although not as common, some patients overreport their 
substance use. For example, a patient suffering from 
untreated or inadequately treated pain may exaggerate 
his or her use of opiates in order to obtain methadone or 
buprenorphine (drugs used to treat opioid addiction) to 
alleviate that pain. Such patients would benefit from treat­
ment by a pain specialist (3).  
Additionally, clinicians may fail to recognize substance use 
disorders because they do not routinely screen for substance 
use, especially in patients who do not look like “typical sub­
stance users.” According to NESARC data, there is no typi­
cal substance user; problem alcohol and drug use occurs in 
people across genders, age-groups, and ethnic backgrounds 
(3). It is important that clinicians evaluate all patients for 
substance use disorders. 
2 Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. 
American Psychiatric Association, 2000. 
THE TERMINOLOGY OF ADDICTION
 
In the American Psychiatric Association’s (APA’s) latest revision of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM–IV–TR), substance use disorders fall into two categories: substance abuse and substance dependence. A person can be 
diagnosed with abuse only if he or she does not fit the criteria for dependence, and a person who meets the criteria for 
both abuse and dependence is diagnosed with dependence. According to the APA, a dependent person cannot control his 
or her substance use; substance dependence is “a cluster of cognitive, behavioral and physiological symptoms indicating 
that the individual continues use of the substance despite significant substance-related problems” (23). 
Some scientists believe that, rather than thinking about abuse and dependence as distinct phenomena, it might be 
more useful to consider a broader concept of “addiction.” In a recent study, Saha and colleagues (24) found that alco­
hol problems occur on a continuum rather than falling into the categories of abuse and dependence. They suggest 
that having two diagnostic categories may be misleading. 
Additionally, O’Brien and colleagues (25) argue that the term “dependence” itself might create confusion, because it 
has more than one meaning. In the DSM–IV–TR, drug and alcohol dependence involve chronic, relapsing, and 
compulsive substance use associated with addiction. However, the term dependence can simply refer to changes in 
the body and brain that cause signs of withdrawal but which are not necessarily associated with addiction—changes 
which might, for example, occur in patients who are taking pain medication or antidepressants as prescribed for legit­
imate medical reasons. Because of such ambiguity, clinicians may be reluctant to prescribe substances such as pain 
medications that can lead to physical dependence (23). 
The term “addiction” also has disadvantages, however. As noted by Drs. Henry Kranzler and T.-K. Li in NIAAA’s 
journal Alcohol Research & Health (23), addiction carries a stigma that might make clinicians less likely to use this 
term for fear of alienating their patients. Additionally, like the term “alcoholism,” addiction is so widely used in such 
different contexts that its meaning is imprecise and unclear (23). 
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Clinicians also may have problems interpreting the 
DSM–IV–TR criteria, making it difficult to accurately 
diagnose substance use disorders. As described in the 
accompanying sidebar, the DSM–IV–TR uses terminology 
that may be confusing. Some clinicians confuse physical 
dependence on a substance (i.e., experiencing withdrawal) 
with the DSM–IV–TR diagnosis of substance dependence. 
In fact, the vast majority of people who meet criteria for 
alcohol dependence do not experience withdrawal symp­
toms when they abruptly discontinue drinking. Additionally, 
some patients whose substance use is hazardous or harmful 
may not meet the criteria for substance abuse (3). Such 
patients still should be evaluated and considered for an 
intervention aimed at reducing their drinking or otherwise 
modifying their behavior. 
Treatment 
Behavioral therapies 
For most patients, the most effective treatment approaches 
combine behavioral treatments (i.e., motivation enhance­
ment therapy [MET] and cognitive-behavioral therapy 
[CBT]) and pharmacological treatments. MET seeks to 
motivate patients who are resistant to treatment, and CBT 
gives people the skills to reduce their drinking or to abstain 
from drinking. Contingency management interventions are 
another tool. These interventions center on rewarding posi­
tive behavior. Behavioral therapy also is an important tool 
for helping patients comply with medication regimens (10). 
For more information on behavioral therapies, see Volume 
1 of the Project Combine monograph series, listed in the 
resources section of this Alert. 
Pharmacotherapies 
In addition to behavioral therapy, pharmacotherapies can 
help patients to curb their use of alcohol and other drugs. 
This section explores traditional and new medications avail­
able to treat alcohol and drug dependence. Volume 2 of 
the Project Combine monograph series provides additional 
information on medication management (see the resources 
section of this Alert). 
Disulfiram. Disulfiram interferes with the breakdown of 
alcohol. When a person taking disulfiram drinks alcohol, 
it causes a buildup of acetaldehyde—a toxic byproduct of 
alcohol—in the body. This causes a variety of unpleasant 
effects, including reddening or flushing of the face and 
neck, nausea, and nervousness. The U.S. Food and Drug 
Administration (FDA) approved disulfiram in 1949 for the 
treatment of alcohol use disorders (10). In a study of 600 
male veterans, overall, disulfiram had no effect on long-term 
abstinence (11). Among individuals who drank, however, 
the active dosage of the medication (250 mg/day) reduced 
the number of days the subjects spent drinking. Disulfiram 
can cause potentially serious effects when combined with 
alcohol, so the patient’s goal must be abstinence (10). 
Patients who respond well to disulfiram tend to be older, 
with greater social stability and motivation for recovery; 
they tend to have a longer drinking history, attend Alcoholics 
Anonymous meetings, and be free of alcohol-related dementia 
and other cognitive problems (12,13). 
Disulfiram may be useful in treating cocaine addiction, 
both by producing an adverse reaction similar to that pro­
duced with alcohol and by reducing the euphoria associated 
with the drug (10). Successful treatment with disulfiram 
requires strict adherence to the medication regimen— 
patients who take disulfiram must be highly motivated to 
continue treatment. 
Naltrexone. Naltrexone blocks the activity of a class of 
molecules (i.e., opiate receptors). These molecules are 
involved in relaying chemical messages in the brain that are 
involved in addiction. In addition to an oral form, the FDA 
has approved a long-acting, injectable form of naltrexone 
for the treatment of alcohol dependence (10). Research 
shows that naltrexone reduces the risk of relapse in heavy 
drinkers; however, there is less evidence that it reduces the 
number of drinking days or that it helps patients to main­
tain total abstinence (14,15). 
Studies also have shown that naltrexone may be useful in 
treating drug use disorders, including opioid and cocaine 
dependence (16). Naltrexone has been approved by the 
FDA for the treatment of opioid dependence; however, 
because it can cause acute withdrawal from opiates (poten­
tially making the patient feel very ill), patients should be 
drug-free for at least 7 days before beginning treatment. 
Additionally, patients should be warned that if they return 
to using opiates heavily, they run the risk of death because 
naltrexone will reduce their tolerance to opiates and put 
them at risk for overdose (10). 
Acamprosate. Acamprosate also affects 
certain chemical messengers  (i.e., neuro­
transmitters) in the brain (10). Although 
the FDA approved acamprosate for 
the treatment of alcohol dependence, 
research with this medication has pro-
duced mixed results. European studies 
(17–19) have shown that acamprosate 
not only reduces the risk of heavy 
“In addition to behavioral therapy, 
pharmacotherapies can help patients 
to curb their use of alcohol and 
other drugs.” 
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drinking, but nearly doubles the likelihood that patients 
will achieve abstinence. These studies suggest that acam­
prosate is most useful in patients who develop alcohol 
dependence later in life, who do not have a family history of 
alcohol dependence, and who display physical dependence 
and higher than usual levels of anxiety (20). It is important 
to note that other studies show that acamprosate is no more 
effective than placebo (21,22). 
Anticonvulsant medications. Topirimate has been shown 
to be an effective treatment for alcohol dependence and 
may be beneficial for cocaine dependence treatment. Other 
anticonvulsants, including carbamazepine and valproate, 
also have shown some effectiveness in treating alcohol use 
disorders, and they may be especially useful in patients with 
co-occurring alcohol dependence and bipolar disorder (10). 
Serotonergic and other medications. Although studies are 
scarce, some research has shown that medications which 
target other mechanisms in the brain (selective serotonin 
reuptake inhibitors [SSRIs], atypical antipsychotic medica­
tions, or lithium) may be useful in treating substance use 
disorders. The medications appear to be particularly useful 
for treating certain subgroups of alcohol-dependent patients, 
based on the age of onset of problem drinking (10). 
Conclusion 
Addictive disorders represent a major health issue both in 
the United States and worldwide. Because alcohol and drug 
dependence are likely to co-occur, exploring how alcohol 
addiction may relate to and interact with other addictions 
is important. Current research is exploring the underlying 
causes of addiction, and why alcohol and other drug use 
disorders co-occur so frequently, as well as how behavioral 
and drug therapies can best treat these disorders. There is 
no “magic bullet” for treating addiction—no treatment will 
work for everyone in every situation. More research is needed 
to identify effective treatments for different populations, 
especially youth, older people, and patients with co-occurring 
psychiatric disorders. Such research is vital to better under­
stand the mechanisms and course of addiction as well as its 
diagnosis and treatment. 
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R e s o u r  c e s  
Source material for this Alcohol Alert originally appeared in Alcohol Research & Health, 
Volume 31, Number 2, 2008. Articles in that issue explore the causes, diagnosis, and 
treatment of alcohol and other drug addiction. Other resources include: 
▲
 
Helping Patients Who Drink Too Much: A Clinician’s Guide. The Guide is a screening tool 
that helps clinicians recognize and diagnose alcohol use disorders. It is available in 
book form and as an accredited electronic-learning course. 
▲
 
Project Combine,Volume 1. Combined Behavioral Intervention Manual: A Clinical 
Research Guide for Therapists Treating People With Alcohol Abuse and Dependence. 
Highlights the use of Combined Behavioral Intervention, an intensive treatment 
that combines several previously evaluated interventions. 
▲
 
Project Combine,Volume 2. Medical Management Treatment Manual: A Clinical 
Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part 
of the Treatment for Alcohol Dependence. Describes the use of medical manage­
ment and brief counseling sessions to enhance medication adherence and absti­
nence from alcohol. 
The Clinician’s Guide, the Project Combine manuals, and full-text articles from each issue of Alcohol Research & 
Health are available on the NIAAA Web site at www.niaaa.nih.gov. Subscriptions to Alcohol Research & Health 
are available from the Superintendent of Documents for $25.Write to New Orders, Superintendent of 
Documents, P.O. Box 371954, Pittsburgh, PA 15250–7954; or fax 202/512–2250. 
Full text of this publication is available on NIAAA’s World Wide Web site at www.niaaa.nih.gov. 
All material contained in the Alcohol Alert is in the public domain and may be used or reproduced 
without permission from NIAAA. Citation of the source is appreciated.
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